uploads/2018/03/Strensiq.png

Alexion Pharmaceuticals: Strensiq and Kanuma in 2017

By

Updated

Strensiq’s revenue trends

In 4Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenues of $95.6 million, which reflected ~35% growth on a YoY (year-over-year) basis and ~10% growth on a quarter-over-quarter basis.

In 4Q17, in the US, Europe, and Asia-Pacific markets, Strensiq reported revenues of $76.2 million, $12.3 million, and $5.3 million, respectively—compared to $59.7 million, $5.4 million, and $3.6 million in 4Q16.

Article continues below advertisement

In fiscal 2017, Strensiq reported revenues of $340 million—compared to $209.4 million in 2016. In 2017, in the US, Europe, and Asia-Pacific markets, Strensiq reported revenues of $280 million, $35.6 million, and $18.6 million, respectively—compared to $177.5 million, $15.3 million, and $13.0 million in 2016.

Strensiq treats perinatal and infantile-onset and juvenile-onset hypophosphatasia.

Kanuma revenue trends

In 4Q17, Kanuma reported revenues of $21.9 million—compared to $11 million in 4Q16. In 4Q17, Kanuma witnessed ~37% growth on a quarter-over-quarter basis.

In 4Q17, in the US, Europe, and Asia-Pacific markets, Kanuma generated revenues of $11.2 million, $5.9 million, and $0.9 million, respectively—compared to $8.4 million, $1.7 million, and $0.4 million in 4Q16.

In fiscal 2017, Kanuma reported revenues of $65.6 million—compared to 29.1 million in 2016.

In 2017, in the US, Europe, and Asia-Pacific markets, Kanuma reported revenues of $42.4 million, $14.6 million, and $2.7 million, respectively—compared to $20.4 million, $6.3 million, and $1.3 million in 2016.

Currently, Kanuma is the only FDA approved drug to treat individuals with lysosomal acid lipase deficiency.

In February 2017, Alexion Pharmaceuticals presented new combined interim data from the ongoing VITAL and CL-08 clinical trials. Alexion Pharmaceuticals’ press release on February 6, 2018, said, “VITAL and CL-08, show a 3-year survival estimate of 68% in infants with rapidly progressive lysosomal acid lipase deficiency (or LAL-D) treated with Kanuma (sebelipase alfa).” To know learn more about the results of the clinical trial, please refer to the press release.

In 2017, Alexion Pharmaceuticals’ peers in the rare metabolic disorder drugs market, Novo Nordisk (NVO), Sanofi (SNY), and Ionis Pharmaceuticals (IONS) reported revenues of $16.9 billion, $39.5 billion, and $507 million, respectively.

Advertisement

More From Market Realist